JP2013528364A - 新規のアレルゲン - Google Patents
新規のアレルゲン Download PDFInfo
- Publication number
- JP2013528364A JP2013528364A JP2013506115A JP2013506115A JP2013528364A JP 2013528364 A JP2013528364 A JP 2013528364A JP 2013506115 A JP2013506115 A JP 2013506115A JP 2013506115 A JP2013506115 A JP 2013506115A JP 2013528364 A JP2013528364 A JP 2013528364A
- Authority
- JP
- Japan
- Prior art keywords
- allergen
- equine
- allergy
- kda
- allergens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 118
- 241000283073 Equus caballus Species 0.000 claims abstract description 126
- 239000012634 fragment Substances 0.000 claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 108050001520 Secretoglobin Proteins 0.000 claims abstract description 11
- 102000011274 Secretoglobin Human genes 0.000 claims abstract description 11
- 238000003745 diagnosis Methods 0.000 claims abstract description 11
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 42
- 208000026935 allergic disease Diseases 0.000 claims description 41
- 230000007815 allergy Effects 0.000 claims description 39
- 229960004784 allergens Drugs 0.000 claims description 35
- 238000009739 binding Methods 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 9
- 229940074608 allergen extract Drugs 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 60
- 102000004169 proteins and genes Human genes 0.000 description 55
- 235000018102 proteins Nutrition 0.000 description 54
- 230000027455 binding Effects 0.000 description 37
- 238000004458 analytical method Methods 0.000 description 33
- 238000000746 purification Methods 0.000 description 31
- 239000000284 extract Substances 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 18
- 230000009257 reactivity Effects 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 208000010668 atopic eczema Diseases 0.000 description 15
- 230000000172 allergic effect Effects 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 12
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 11
- 238000009169 immunotherapy Methods 0.000 description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000001542 size-exclusion chromatography Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 241000282326 Felis catus Species 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 206010070834 Sensitisation Diseases 0.000 description 8
- 238000000955 peptide mass fingerprinting Methods 0.000 description 8
- 230000008313 sensitization Effects 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000009260 cross reactivity Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000005571 anion exchange chromatography Methods 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 210000000540 fraction c Anatomy 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 102000019298 Lipocalin Human genes 0.000 description 4
- 108050006654 Lipocalin Proteins 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 3
- 102000028554 IgE binding proteins Human genes 0.000 description 3
- 108091009324 IgE binding proteins Proteins 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 125000000539 amino acid group Chemical class 0.000 description 3
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000010181 skin prick test Methods 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 101000653197 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB3 Proteins 0.000 description 2
- 101000739193 Bos taurus Secretoglobin family 1D member Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101710198774 Envelope protein US9 Proteins 0.000 description 2
- 241000283087 Equus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 240000001973 Ficus microcarpa Species 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010073310 Occupational exposures Diseases 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003918 fraction a Anatomy 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 231100000675 occupational exposure Toxicity 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- YIFLQBNCXIFWEL-KBXCAEBGSA-N 1-(7-methoxy-benzo[1,3]dioxol-5-yl)-1,2-bis-(2-methyl-but-2-enoyloxy)-propane Natural products COc1cc(cc2OCOc12)[C@H](OC(=O)C(=CC)C)[C@H](C)OC(=O)C(=CC)C YIFLQBNCXIFWEL-KBXCAEBGSA-N 0.000 description 1
- YIFLQBNCXIFWEL-UHFFFAOYSA-N 2-epilaserine Natural products COc1cc(cc2OCOc12)C(OC(=O)C(=C/C)C)C(C)OC(=O)C(=C/C)C YIFLQBNCXIFWEL-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241000497851 Anaphes Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000636168 Grapevine leafroll-associated virus 3 (isolate United States/NY1) Movement protein p5 Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710085995 Latherin Proteins 0.000 description 1
- 101000878457 Macrocallista nimbosa FMRFamide Proteins 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 241000080590 Niso Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000008557 Parietaria judaica pollen Substances 0.000 description 1
- 208000008267 Peanut Hypersensitivity Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 101100537665 Trypanosoma cruzi TOR gene Proteins 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 230000037446 allergic sensitization Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 239000013574 grass pollen allergen Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 201000010853 peanut allergy Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 201000004335 respiratory allergy Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1050406-6 | 2010-04-23 | ||
| SE1050406 | 2010-04-23 | ||
| PCT/SE2011/050503 WO2011133105A1 (en) | 2010-04-23 | 2011-04-26 | Novel allergen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016029444A Division JP6280578B2 (ja) | 2010-04-23 | 2016-02-19 | 新規のアレルゲン |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2013528364A true JP2013528364A (ja) | 2013-07-11 |
Family
ID=44834387
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013506115A Pending JP2013528364A (ja) | 2010-04-23 | 2011-04-26 | 新規のアレルゲン |
| JP2016029444A Active JP6280578B2 (ja) | 2010-04-23 | 2016-02-19 | 新規のアレルゲン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016029444A Active JP6280578B2 (ja) | 2010-04-23 | 2016-02-19 | 新規のアレルゲン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9164101B2 (enExample) |
| EP (1) | EP2560990B1 (enExample) |
| JP (2) | JP2013528364A (enExample) |
| CN (1) | CN103108883B (enExample) |
| AU (1) | AU2011243277B2 (enExample) |
| CA (1) | CA2794556C (enExample) |
| DK (1) | DK2560990T3 (enExample) |
| ES (1) | ES2592956T3 (enExample) |
| RU (1) | RU2608494C2 (enExample) |
| WO (1) | WO2011133105A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017524358A (ja) * | 2014-07-21 | 2017-08-31 | ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ | 新規アレルゲン |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2285042C2 (ru) * | 2000-11-16 | 2006-10-10 | Альк-Абелло А/С | Новые мутантные аллергены |
| CN101588815B (zh) * | 2006-12-22 | 2013-10-23 | 法蒂亚公司 | 新前列腺激肽释放酶过敏原 |
-
2011
- 2011-04-26 WO PCT/SE2011/050503 patent/WO2011133105A1/en not_active Ceased
- 2011-04-26 EP EP11772331.2A patent/EP2560990B1/en active Active
- 2011-04-26 ES ES11772331.2T patent/ES2592956T3/es active Active
- 2011-04-26 RU RU2012150039A patent/RU2608494C2/ru active
- 2011-04-26 AU AU2011243277A patent/AU2011243277B2/en active Active
- 2011-04-26 JP JP2013506115A patent/JP2013528364A/ja active Pending
- 2011-04-26 US US13/642,259 patent/US9164101B2/en active Active
- 2011-04-26 CN CN201180020467.7A patent/CN103108883B/zh active Active
- 2011-04-26 CA CA2794556A patent/CA2794556C/en active Active
- 2011-04-26 DK DK11772331.2T patent/DK2560990T3/en active
-
2015
- 2015-09-29 US US14/869,362 patent/US9724407B2/en active Active
-
2016
- 2016-02-19 JP JP2016029444A patent/JP6280578B2/ja active Active
Non-Patent Citations (5)
| Title |
|---|
| JPN6015012067; Ｊ． Ａｌｌｅｒｇｙ Ｃｌｉｎ． Ｉｍｍｕｎｏｌ． （１９９６） ｖｏｌ．９８， ｎｏ．１， ｐ．１６９-１７１ * |
| JPN6015012069; Ａｌｌｅｒｇｙ （１９９３） ｖｏｌ．４８， ｐ．５３５-５４１ * |
| JPN6015012072; Ｅｕｒ． Ｊ． Ｂｉｏｃｈｅｍ． （１９９８） ｖｏｌ．２５３， ｐ．２０２-２１１ * |
| JPN6015012073; Ｉｎｔ． Ａｒｃｈ． Ａｌｌｅｒｇｙ Ｉｍｍｕｎｏｌ． （２０００） ｖｏｌ．１２３， ｎｏ．３， ｐ．２２０-２２７ * |
| JPN6015012075; Ｓｃｉｅｎｃｅ （２００９） ｖｏｌ． ３２６， ｎｏ． ５９５４， ｐｐ． ８６５-８６７ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017524358A (ja) * | 2014-07-21 | 2017-08-31 | ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ | 新規アレルゲン |
Also Published As
| Publication number | Publication date |
|---|---|
| DK2560990T3 (en) | 2016-09-26 |
| JP6280578B2 (ja) | 2018-02-14 |
| RU2012150039A (ru) | 2014-05-27 |
| CA2794556C (en) | 2018-12-04 |
| AU2011243277B2 (en) | 2014-01-16 |
| EP2560990B1 (en) | 2016-06-22 |
| CA2794556A1 (en) | 2011-10-27 |
| US9164101B2 (en) | 2015-10-20 |
| JP2016175891A (ja) | 2016-10-06 |
| CN103108883A (zh) | 2013-05-15 |
| AU2011243277A1 (en) | 2012-10-25 |
| CN103108883B (zh) | 2015-06-03 |
| RU2608494C2 (ru) | 2017-01-18 |
| EP2560990A1 (en) | 2013-02-27 |
| US20130045233A1 (en) | 2013-02-21 |
| US20160082101A1 (en) | 2016-03-24 |
| ES2592956T3 (es) | 2016-12-02 |
| US9724407B2 (en) | 2017-08-08 |
| EP2560990A4 (en) | 2013-11-27 |
| WO2011133105A1 (en) | 2011-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9274114B2 (en) | Prostate kallikrein allergen | |
| JP6280578B2 (ja) | 新規のアレルゲン | |
| RU2592674C2 (ru) | Аллергены, полученные рекомбинантными способами | |
| CN106604929B (zh) | 新型过敏原 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140408 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150326 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150626 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150708 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20151021 |